Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Chimerix Inc Market Cap
From what 6 stock analysts predict, the share price for Chimerix Inc (CMRX) might increase by 676.14% in the next year. This is based on a 12-month average estimation for CMRX. Price targets go from $5 to $11. The majority of stock analysts believe CMRX is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assigned CMRX 0 buy ratings, 5 hold ratings, and 1 sell ratings. This means that analysts expect Chimerix Inc to generate similar returns as the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CMRX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CMRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Edward White HC Wainwright & Co. | Buy | $11 | Reiterates | Aug 14, 2024 |
| Edward White HC Wainwright & Co. | Buy | $11 | Reiterates | Mar 1, 2024 |
| David Nierengarten Wedbush | Outperform | $6 | Reiterates | Aug 17, 2023 |
| Edward White HC Wainwright & Co. | Buy | $11 | Reiterates | Aug 16, 2023 |
| Edward White HC Wainwright & Co. | Buy | $11 | Reiterates | Aug 4, 2023 |
| Joel Beatty Baird | Outperform | $7 | Initiates | May 23, 2023 |
| Edward White HC Wainwright & Co. | Buy | $11 | Reiterates | May 5, 2023 |
| Edward White HC Wainwright & Co. | Buy | $11 | Reiterates | Mar 3, 2023 |
| Naureen Quibria Capital One | Overweight | $7 | Initiates | Sep 7, 2022 |
| Edward White HC Wainwright & Co. | Buy | $11 | Maintains | May 17, 2022 |
| Edward White HC Wainwright & Co. | Buy | $24 | Maintains | Dec 22, 2021 |
| Edward White HC Wainwright & Co. | Buy | $21 | Maintains | Nov 22, 2021 |
| Edward White HC Wainwright & Co. | Buy | $19 | Maintains | Jun 7, 2021 |
HC Wainwright & Co. | Buy | $18 | Maintains | May 6, 2021 |
Maxim Group | Buy | Initiates | Apr 29, 2021 | |
Wedbush | Outperform | Initiates | Mar 31, 2021 | |
Jefferies | Buy | Initiates | Mar 31, 2021 | |
HC Wainwright & Co. | Buy | $16 | Maintains | Jan 11, 2021 |
Citigroup | Neutral | $2 | Maintains | Mar 6, 2019 |
JP Morgan | Underweight | Downgrade | Feb 14, 2018 |
When did it IPO
2013
Staff Count
72
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Michael T. Andriole M.B.A.
Market Cap
$89.3M
In 2023, CMRX generated $324,000 in revenue, which was a decrease of -99.04% from the previous year. This can be seen as a signal that CMRX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Chimerix, Inc. (NASDAQ:CMRX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Officer Michelle LaSpaluto - Chief Financial Officer Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Soumit Roy - Jones Research Ed White - HC Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Chimerix Second Quarter 2024 Earnings Conference Call.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.
Fri, 05 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
Thu, 30 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.
Wed, 01 May 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Chimerix, Inc. (NASDAQ:CMRX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will O'Connor – Stern Investor Relations Mike Andriole – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Josh Allen – Chief Technology Officer Michelle LaSpaluto – Chief Financial Officer Tom Riga – Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft – Jefferies Naureen Quibria – Capital One Soumit Roy – Jones Research Troy Langford – TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor of Stern Investor Relations.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
